266results about "Saccharide compounds with non-saccharide radicals" patented technology

Disclosed is an analgesic agent for a non-inflammatory pain disease, which comprises a sialic acid or a pharmaceutically acceptable salt thereof as an active ingredient. The sialic acid which is an active ingredient for the agent has an analgesic effect on a disease model animal of neurogenic pain which is a non-inflammatory pain. Therefore, the analgesic agent is useful as a pharmaceutical agent for the treatment of a non-inflammatory pain disease such as a neurogenic pain disease, e.g. trigeminal neuralgia, postherpetic neuralgia, entrapment neuropathy, complex regional pain syndrome, diabetic neuropathy, traumatic neuropathy, phantom limb pain, central pain after spinal cord injury or stroke, and neuropathy caused by pharmacotherapy or radiation therapy, or the like.

The present invention provides a process for preparing a sugar chain asparagine derivative. According to the process, various isolated sugar chain asparagine derivatives useful in the field of the development of pharmaceuticals and the like can be conveniently obtained in a large amount as compared to that of the prior art. The present invention also provides a process for preparing a sugar chain asparagine and a process for preparing a sugar chain via a step for preparing a sugar chain asparagine derivative. The present invention further provides a novel sugar chain asparagine derivative, a sugar chain asparagine and a sugar chain.

A process for obtaining one or more than one salt of an organic acid(s), or organic acid(s), from an aqueous sugar stream comprising one or more than one mineral acid and the organic acid(s) is provided. The process comprises introducing the aqueous sugar stream to a separation system comprising one or more beds of anion exchange resin and obtaining a stream therefrom comprising the sugar. The one or more beds of anion exchange resin are then regenerated in one or more stages to produce at least one product stream comprising the organic acid, a salt of the organic acid, or a combination thereof, and a separate outlet stream comprising the mineral acid, a salt of the mineral acid, or a combination thereof. The product stream is then recovered. The separation may be conducted with two separation units, or using a single anion exchange unit.

C-glycoside compounds are suited for stimulating the synthesis of glycosaminoglycans containing a D-glucosamine and/or N-acetyl-D-glucosamine residue, advantageously hyaluronic acid, and/or proteoglycans, advantageously proteoglycans containing hyaluronic acid, by fibroblasts and/or keratinocytes.

An amphiphilic compound is provided capable of forming vesicles or liposomes, said amphiphilic compound having at least one headgroup containing a selectively cleavable group or moiety such as a residue of a choline or phenylalanine derivative, and at least one hydrogen-bonding group located either within said headgroup and/or in close proximity thereto. The cleavable group or moiety is cleaved under selective conditions including change of chemical, physical or biological environment and is preferably cleaved enzymatically in a biological environment such as the brain or the blood. Vesicles or liposomes made from said amphiphilic compounds are suitable for delivery of a therapeutic substance or a diagnostic agent specifically to a target organ or tissue, or for delivery of a nucleic acid for gene therapy.

The invention relates to a method for preparing bagasse dissolving pulp and pre-extracting hemicellulose and products thereof; the method comprises the following steps: bagasse preparation which comprises the steps of depithing and washing; prehydrolysis which is carried out in a globe digester or a hydrolysis boiler; wherein, the process conditions are as follows: in the process for depithing and oven-drying bagasse, the solid-to-liquid ratio is 1:0.4-8.0, the hydrolysis temperature is 100-200 DEG C, the hydrolysis time is 15-240min, the pH value of the end point of hydrolysis is 2-5; in the process of the solid-to-liquid separation and washing, the filtrate is collected to prepare extracting solution; dissolving pulp is prepared by residue alkali method. By adopting the method, bagasse dissolving pulp and bagasse extracting solution which is used to prepare oligosaccharides are obtained. Most of pentosan in bagasse can be extracted by controlling the process conditions of the prehydrolysis, the technical route and the process conditions have strong pertinence so that the reactivity and the uniformity of bagasse dissolving pulp can be improved; by improving the traditional dissolving pulp alkali method for pulping, bagasse biorefinery based on dissolving pulp pulping can be realized in engineering so that the production costs for preparing bagasse dissolving pulp and pre-extracting hemicellulose are reduced.

The invention relates to the discovery that specific adamantyl or adamantyl group derivatives containing retinoid-related compounds induce apoptosis of cancer cells and therefore may be used for the treatment of cancer, including advanced cancer. Also, the present invention relates to novel adamantyl or adamantyl group derivatives containing retinoid compounds and their usage for treatment and/or prevention of cancer, keratinization disorders, dermatological conditions, and other therapies More specifically, it has been shown that such adamantyl compounds, e.g., 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid, 2-[3-(1-adamantyl)-4-methoxyphenyl]-5-benzimidazole carboxylic acid, and 6-[3-(1-adamantyl)-4,5-methylenedioxyphenyl]-2-naphthoic acid, can be used to treat or prevent cervical cancers and precancers such as cervical dysplasias, including high grade and low grade dysplasias.

The present invention provides nitrogen-containing fused cyclic derivatives represented by the following general formula or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications or obesity, in the formula one of R¹ and R⁴ represents a group represented by the following general formula (S) (in which R⁵ and R⁶ represent H, OH, a halogen atom, etc.; Q represents an alkylene group etc.; and ring A represents an aryl group etc.), and the other represents H, OH, an amino group, etc.; R² and R³ represent H, OH, an amino group, a halogen atom, and an optionally substituted alkyl group, etc.; A¹ represents O, S, etc.; A² represents CH or N; G represents a group represented by the following general formula (G-1) or (G-2) (E¹ represents H, F or OH; and E² represents H, F, a methyl group, etc.), and pharmaceutical compositions comprising the same, and pharmaceutical uses thereof.

The invention discloses a method for extracting sialic acid from bird nests by means of crystallization. The method comprises the steps of soaking the bird nests with deionized water and removing impurities; then pulping and crushing, heating under a high pressure, centrifuging, drying, dissolving and crystallizing to obtain the sialic acid. According to the method disclosed by the invention, hydrolysis of the glycoproteins of the bird nests is accelerated through serious heating by means of high-pressure heating, and the combined-state sialic acid is converted to a free-state sialic acid; the high-pressure heating avoids the introduction of other ingredients, thereby simplifying the subsequent separation and purification steps; the sialic acid crude product obtained by freeze-drying is prepared into alcohol-saturated solution by virtue of the property that the sialic acid is slightly dissolved in alcohol but proteins and polysaccharides are insoluble in alcohol, and therefore on one hand, the impurities such as alcohol-insoluble proteins and polysaccharides are removed, on the other hand, the solvent polarity is changed by adding a non-polar solvent, and sialic acid crystals are obtained according to the different seperation sequences of the sialic acid and the impurities. According to the method disclosed by the invention, sialic acid extraction steps are simplified, and industrial pollution is reduced.

The invention relates to a bagasse alkaline pulping method by pre-extracting hemicellulose and a product thereof; the method includes the following steps of: preparing bagasse: depithing and washing the bagasse; pre-extraction, in which the extracted solvent is sodium hydroxide solution and the technical condition comprises an alkaline content of 1-8percent, a solid-to-liquid ratio of 1:2.5-8.0, extraction temperature of 80-180 DEG C, heating-up time of 10-120 minutes, holding time of 0-120 minutes, a pH value of 4.5-6.9 at a reaction end point, and the pressure of saturated steam pressure at corresponding temperature; liquid solid separation and washing: collecting filtrate to produce extract; and preparing the pulp by residue alkaline process. In the invention, bagasse extract capable of extracting xyio-oligosacchandes, and the like and bagasse rough pulp for preparing whitened chemical pulp can be obtained; with a pre-extraction procedure added before stewing, the unscreened yield and hardness of bagasse are equivalent to that of pure pulping without pre-extraction by controlling the pre-extraction and stewing technical condition; bagasse biological refining on a pulping basis is realized; and the cost for pulping and pre-extracting hemicellulose is reduced, thereby saving resources.

The invention discloses a method for separating hyaluronate tetrasaccharide from hyaluronate hexasaccharide, and belongs to the technical field of bioengineering. The method comprises the following steps: adopting Q Sepharose fast flow as an ion exchanger, Tris-HCl with the pH value of 8-9 as an equilibrium liquid, and 0.125 M NaCl with the pH value of 8, performing linear gradient elution to separate hyaluronate tetrasaccharide from hyaluronate hexasaccharide, and desalting to obtain pure products of hyaluronate tetrasaccharide and hyaluronate hexasaccharide.

The invention relates to a novel admixture for mineral binders, composed of a composition containing at the same time a sugar or an oxidized sugar and a hydrogenated sugar. The oxidized sugar may consist, in particular, of gluconic acid or one of its salts or an oxidized starch hydrolysate. The hydrogenated sugar may consist in particular of maltitol, sorbitol, mannitol, xylitol, arabitol, or a hydrogenated starch hydrolysate containing at least 40% by weight of maltitol. Within the admixture, this composition may be combined with conventional admixtures such as phosphates, borates, or amines. The combination of a sugar or an oxidized sugar and a hydrogenated sugar within this composition makes it possible to obtain synergistic effects, particularly in terms of plasticity and mechanical properties of the mineral binders. The admixtures claimed may be used equally well for admixing with cements, raw materials for cements as for admixing with mortars, slurries and concretes. They may also be used in other sectors such as, for example, the plaster industry, particularly as complexing agents or hydration or dehydration controllers.

The invention discloses a novel scutellarin derivative as well as a preparation method and a pharmaceutical composition thereof. The compound is prepared by the two-step reaction of methyl etherification and acetylation of the scutellarin functioning as an initial raw material and the separation and has the chemical name of 4',5,6-trimethoxy-8-(3,4,5-triacetyl-glucuronic acid)-scutellarin. The compound and the pharmaceutical composition thereof can be used for treating cardiovascular and cerebrovascular disease, phlegmasia and tumor and has the advantages of good dissolvability, high bioavailability and remarkable curative effect.